Nuvation Bio Inc. (NUVB) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.43B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.61M; Retained Earnings (Accumulated Deficit)USD $-1.17B; Stockholders' Equity Attributable to ParentUSD $253.86M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.43B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.68M; Retained Earnings (Accumulated Deficit)USD $-1.11B; Stockholders' Equity Attributable to ParentUSD $319.56M.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.42B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-187.00K; Retained Earnings (Accumulated Deficit)USD $-1.12B; Stockholders' Equity Attributable to ParentUSD $305.72M.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.40B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-139.00K; Retained Earnings (Accumulated Deficit)USD $-1.08B; Stockholders' Equity Attributable to ParentUSD $325.88M.
Nuvation Bio Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD | Common Stocks, Including Additional Paid in Capital USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.43B | $-2.61M | $-1.17B | $253.86M | 3 month · $-17.14M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.43B | $-1.68M | $-1.11B | $319.56M | 3 month · $9.03M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.42B | $-187.00K | $-1.12B | $305.72M | 12 month · $35.89M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.40B | $-139.00K | $-1.08B | $325.88M | 3 month · $8.02M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.40B | $-327.00K | $-1.02B | $372.91M | 3 month · $12.03M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.38B | $545.00K | $-963.98M | $419.46M | 3 month · $7.85M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.37B | $573.00K | $-910.74M | $463.79M | 12 month · $32.27M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.36B | $1.38M | $-861.30M | $502.71M | 3 month · $7.48M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.08B | $-1.27M | $-820.09M | $257.19M | 3 month · $9.57M | $274.94M | (m) | (m) | (m) |
| 2024-03-31 | $952.81M | $-1.17M | $-357.60M | $594.04M | 3 month · $5.04M | (m) | (m) | (m) | $116.99M |
| 2023-12-31 | $947.75M | $181.00K | $-342.80M | $605.12M | 12 month · $19.51M | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | $943.90M | $-3.30M | $-329.02M | $611.59M | 3 month · $5.43M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $938.39M | $-4.39M | $-309.37M | $624.63M | 3 month · $5.52M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $932.74M | $-2.94M | $-288.73M | $641.07M | 3 month · $4.84M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $927.60M | $-5.53M | $-267.00M | $655.08M | 12 month · $16.29M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $922.21M | $-8.12M | $-246.16M | $667.93M | 3 month · $2.94M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $919.01M | $-6.98M | $-218.95M | $693.08M | 3 month · $4.79M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $913.88M | $-6.22M | $-184.10M | $723.56M | 3 month · $3.58M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $909.99M | $-1.19M | $-162.80M | $746.00M | 12 month · $9.27M | (m) | (m) | (m) | (m) |
| 2021-09-30 | $906.65M | $388.00K | $137.67M | $769.37M | 3 month · $2.75M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $903.87M | $757.00K | $115.69M | $788.93M | 3 month · $2.15M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $901.72M | $981.00K | $96.36M | $806.34M | 3 month · $1.57M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $289.48M | $1.56M | $-75.95M | $215.08M | 12 month · $2.20M | $0.00 | $23.22M | 12 month · $22.60M | (m) |
| 2020-09-30 | $91.00 | $1.82M | $-735.27K | $91.85M | 3 month · $348.00K | (m) | $5.73M | (m) | (m) |
| 2020-06-30 | (m) | $2.17M | $-1.00K | $102.88M | 3 month · $389.00K | (m) | $24.64K | (m) | (m) |
| 2020-04-23 | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.24M | (m) | $110.16M | 3 month · $340.00K | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $421.00K | (m) | $117.75M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |